Regardless of the tremendous research and development efforts, nanomedicines are not yet used to their full potential due to their challenging manufacturing requirements. The presented research conducted under the European Union-funded PRECIOUS project aims to develop an industrial process for the production of poly(lactic-co-glycolic acid) (PLGA)-based particles to support the clinical and commercial production of immunomodulatory nanomedicines. The mission was to analyze and evaluate different technologies with respect to their ability to generate PLGA-based nanomedicines and transfer the knowledge to a large scale. In the end, a holistic industrial process including production, purification and storage of the formulation was developed. Overall, this work can be considered a breakthrough for the industrial production of PLGA-based nanoformulations, paving the way for the production and commercialization of future nanomedicines for the fight against cancer and beyond.
The lab-scale and large-scale formulations produced maintained the same functional similarities, underscoring the efficacy of the formulation regardless of the scale of production. Overall, the project resulted in the development of a scalable, robust, and continuous process for the industrial production of PLGA-based nanomedicines for clinical and commercial development.